AbbVie (NYSE:ABBV - Get Free Report) had its price target lifted by Barclays from $325.00 to $335.00 in a research report issued on Monday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Barclays's target price would indicate a potential upside of 12.33% from the stock's previous close.
A number of other research analysts also recently issued reports on the company. Bank of America reissued a "buy" rating on shares of AbbVie in a research note on Tuesday, September 8th. Argus upped their target price on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Erste Group Bank raised AbbVie from a "hold" rating to a "buy" rating in a research note on Wednesday, August 5th. Canaccord Genuity Group lifted their target price on AbbVie from $290.00 to $338.00 and gave the stock a "buy" rating in a report on Monday, November 2nd. Finally, Morgan Stanley boosted their price target on AbbVie from $310.00 to $346.00 and gave the company an "overweight" rating in a research note on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $297.85.
Get Our Latest Report on AbbVie
AbbVie Price Performance
NYSE ABBV traded up $3.19 during mid-day trading on Monday, reaching $298.22. 493,930 shares of the stock were exchanged, compared to its average volume of 6,270,022. AbbVie has a one year low of $190.75 and a one year high of $302.93. The stock has a 50 day simple moving average of $275.51 and a 200-day simple moving average of $240.91. The stock has a market cap of $527.14 billion, a P/E ratio of 51.41, a P/E/G ratio of 1.34 and a beta of 0.20.
AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The business had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same quarter in the previous year, the business earned $1.86 earnings per share. AbbVie's revenue for the quarter was up 10.3% on a year-over-year basis. Sell-side analysts anticipate that AbbVie will post 13.98 EPS for the current fiscal year.
Insiders Place Their Bets
In other AbbVie news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the sale, the executive vice president directly owned 83,171 shares of the company's stock, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company's stock.
Institutional Trading of AbbVie
Large investors have recently made changes to their positions in the company. State Street Corp increased its holdings in shares of AbbVie by 0.3% during the third quarter. State Street Corp now owns 82,815,387 shares of the company's stock valued at $21,663,677,000 after acquiring an additional 218,639 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of AbbVie by 252.6% during the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company's stock worth $8,760,498,000 after purchasing an additional 23,991,451 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company's stock worth $3,590,323,000 after purchasing an additional 106,091 shares in the last quarter. Legal & General Group Plc bought a new position in shares of AbbVie in the 2nd quarter worth $2,905,952,000. Finally, Deutsche Bank AG lifted its holdings in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company's stock worth $2,710,905,000 after purchasing an additional 1,241,587 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
AbbVie Company Profile
(
Get Free Report)
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.